Mosaic ImmunoEngineering, Inc. (CPMV)
OTCMKTS · Delayed Price · Currency is USD
0.6950
0.00 (0.00%)
May 20, 2026, 9:30 AM EST
Mosaic ImmunoEngineering Employees
As of December 31, 2025, Mosaic ImmunoEngineering had 7 total employees, including 2 full-time and 5 part-time employees. The number of employees decreased by 1 or -12.50% compared to the previous year.
Employees
7
Change (1Y)
-1
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$137,569
Market Cap
5.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -1 | -12.50% | 2 | 5 |
| Dec 31, 2024 | 8 | 0 | - | 2 | 6 |
| Dec 31, 2023 | 8 | 0 | - | 3 | 5 |
| Dec 31, 2022 | 8 | 1 | 14.29% | 4 | 4 |
| Dec 31, 2021 | 7 | 0 | - | 3 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptimmune Therapeutics | 506 |
| Brainstorm Cell Therapeutics | 20 |
| Reviva Pharmaceuticals Holdings | 14 |
| AccuStem Sciences | 4 |
| Bioxytran | 2 |
| Synlogic | 1 |
Mosaic ImmunoEngineering News
- 2 years ago - Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. - Accesswire
- 3 years ago - Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101 - Accesswire
- 3 years ago - UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform - Accesswire
- 3 years ago - Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Plat-form - Accesswire
- 4 years ago - Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University - Accesswire
- 4 years ago - Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma - Accesswire
- 4 years ago - Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation - Accesswire
- 4 years ago - Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference - Accesswire